Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting

ConferenceMCO-010Optogenetic TherapyPositive

AI Analysis

Summary

Nanoscope Therapeutics will present data on optogenetic therapy and 3-year follow-up results from the RESTORE Phase 2b/3 trial of MCO-010 for retinitis pigmentosa at the 2026 American Society of Retina Specialists Annual Scientific Meeting.

Clinical Trial Data

Phase

Phase 2b/3

Importance:5/10

Sentiment:

0.60

optogeneticsretinal diseaseretinitis pigmentosamacular degenerationPhase 2b/3follow-up dataconference presentation

Related Companies

$ATALF $TRAX

Read the original article

Published by PR Newswire Clinical Trials on July 10, 2026 1:00 PM

Read Original